Hyperandrogenism Medical Services in China

Hyperandrogenism is a clinical endocrine disorder characterized by excessive production or heightened peripheral activity of androgens—male sex hormones such as testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS)—in individuals assigned female at birth. It is not a disease in itself but rather a biochemical and phenotypic manifestation of underlying pathophysiology, most commonly associated with polycystic ovary syndrome (PCOS), which accounts for approximately 70–80% of cases. Other etiologies include non-classical congenital adrenal hyperplasia (NCAH), adrenal or ovarian tumors, Cushing’s syndrome, hyperprolactinemia, and insulin resistance–driven ovarian theca cell overstimulation. Pathogenesis involves dysregulation across the hypothalamic–pituitary–ovarian–adrenal axes, often amplified by genetic susceptibility, chronic low-grade inflammation, and adipose tissue dysfunction that enhances aromatase activity and androgen conversion. Epidemiologically, hyperandrogenism affects an estimated 5–10% of women of reproductive age globally, with prevalence rising to 12–20% in populations with high obesity rates or PCOS diagnosis. Risk factors include obesity (especially central adiposity), family history of PCOS or early-onset metabolic disease, insulin resistance, sedentary lifestyle, and exposure to endocrine-disrupting chemicals. Clinical manifestations span dermatologic (hirsutism, acne, androgenic alopecia), menstrual (oligo- or amenorrhea), metabolic (dyslipidemia, impaired glucose tolerance), and reproductive domains (anovulation, subfertility). Importantly, hyperandrogenism significantly impairs quality of life: patients report higher rates of anxiety, depression, body image distress, sexual dysfunction, and social withdrawal—often underrecognized in routine care. Untreated, it confers long-term risks including type 2 diabetes, cardiovascular disease, endometrial hyperplasia, and infertility. Early diagnosis requires integrated assessment: detailed history, physical exam (Ferriman-Gallwey score for hirsutism), serum androgen panel (total/free testosterone, DHEAS, androstenedione), AMH, pelvic ultrasound, and exclusion of malignancy or rare endocrinopathies. Management must be individualized—not solely hormone-suppressive—but centered on metabolic health, psychological support, and fertility preservation, especially within reproductive medicine departments where multidisciplinary coordination with endocrinology, dermatology, nutrition, and mental health specialists is essential.

Hyperandrogenism is a clinical endocrine disorder characterized by excessive circulating androgen levels or increased peripheral androgen activity, commonly presenting with hirsutism, acne, alopecia, menstrual irregularities (e.g., oligo- or amenorrhea), and infertility. In the Department of Reproductive Medicine, hyperandrogenism is most frequently associated with polycystic ovary syndrome (PCOS), though other etiologies—including non-classical congenital adrenal hyperplasia (NCAH), hyperprolactinemia, Cushing’s syndrome, and androgen-secreting tumors—must be systematically excluded via biochemical evaluation (total and free testosterone, DHEA-S, androstenedione, 17-hydroxyprogesterone, prolactin, cortisol, ACTH) and pelvic ultrasound. Management is individualized based on symptom severity, reproductive goals, metabolic comorbidities (e.g., insulin resistance, obesity, dyslipidemia), and patient preference.

Conservative treatment forms the cornerstone of initial management, particularly for overweight or obese patients with PCOS-related hyperandrogenism. Lifestyle modification—including structured caloric restriction (500–750 kcal/day deficit), moderate-intensity aerobic and resistance exercise (≥150 minutes/week), and behavioral counseling—has demonstrated robust efficacy: weight loss of ≥5% body weight consistently improves ovarian function, reduces free testosterone by 20–30%, restores ovulation in ~60% of anovulatory women, and enhances insulin sensitivity. Dietary approaches emphasizing low glycemic index foods, high-fiber intake, and adequate protein support hormonal balance and mitigate postprandial hyperinsulinemia, which exacerbates ovarian androgen synthesis. Sleep hygiene optimization and stress reduction techniques (e.g., mindfulness-based stress reduction) are adjunctive, given the bidirectional relationship between hypothalamic-pituitary-adrenal axis dysregulation and androgen excess.

Pharmacologic therapy is indicated when conservative measures are insufficient or contraindicated, or when rapid symptom control is required. First-line agents include combined oral contraceptives (COCs) containing ethinyl estradiol (20–35 μg) and anti-androgenic progestins (e.g., drospirenone, cyproterone acetate, or dienogest). COCs suppress LH-driven ovarian androgen production, increase sex hormone-binding globulin (SHBG), and reduce free testosterone bioavailability; clinical improvement in hirsutism typically requires 6–12 months. For patients desiring conception or intolerant to COCs, insulin-sensitizing agents are pivotal: metformin (1500–2000 mg/day) improves ovulation rates and reduces hyperandrogenemia, especially in insulin-resistant individuals. Spironolactone (50–200 mg/day), a competitive androgen receptor antagonist, is highly effective for hirsutism and acne but is contraindicated in pregnancy and requires monthly pregnancy testing and concomitant contraception. Finasteride (2.5–5 mg/day), a 5α-reductase inhibitor, may be added for refractory hirsutism, though evidence remains less robust than for spironolactone. In select cases—such as NCAH—low-dose glucocorticoids (e.g., hydrocortisone 10–20 mg/day) suppress adrenal androgen overproduction. Gonadotropin-releasing hormone (GnRH) analogues are reserved for severe, treatment-refractory cases due to their profound hypoestrogenic effects and bone mineral density risks.

Surgical intervention is rarely indicated but plays a defined role in specific contexts. Laparoscopic ovarian drilling (LOD) remains a second-line fertility treatment for clomiphene-resistant anovulatory PCOS. Performed under general anesthesia, LOD involves creating 4–10 punctures (3–5 mm depth) in each ovary using monopolar or bipolar energy, thereby reducing theca cell mass and local intraovarian androgen production. Meta-analyses report ovulation resumption in 70–80% and pregnancy rates of 50–60% within 12 months post-procedure, with lower multiple gestation risk compared to gonadotropin therapy. However, LOD carries procedural risks—including adhesion formation, ovarian failure (rare), and potential long-term decline in AMH—and is thus reserved for carefully selected patients after thorough counseling. Adrenalectomy or oophorectomy is only considered for confirmed, unilateral androgen-secreting adrenal or ovarian tumors, confirmed via imaging (contrast-enhanced CT/MRI) and selective venous sampling when localization is uncertain.

Treatment advantages in China reflect integrated, multidisciplinary care models increasingly adopted in tertiary reproductive medicine centers. These institutions offer standardized diagnostic algorithms aligned with international guidelines (e.g., Androgen Excess and PCOS Society criteria) while incorporating traditional Chinese medicine (TCM) adjuncts—such as acupuncture and herbal formulations (e.g., modified Gui Zhi Fu Ling Wan)—with emerging evidence supporting synergistic improvements in insulin sensitivity and menstrual regularity. Advanced digital health platforms enable remote monitoring of anthropometrics, glucose profiles, and medication adherence, enhancing longitudinal care continuity. Moreover, China’s national health insurance system now covers key diagnostics (e.g., serum androgen panels, pelvic ultrasound) and first-line therapeutics (metformin, spironolactone, COCs) at subsidized rates, improving accessibility. Robust clinical trial infrastructure supports rapid translation of novel therapies, including next-generation anti-androgens and selective androgen receptor modulators currently under phase II investigation in Shanghai and Beijing centers.

Recovery and long-term management emphasize sustained lifestyle engagement and vigilant surveillance. Patients should undergo annual assessment of fasting glucose, HbA1c, lipid profile, blood pressure, and BMI; transvaginal ultrasound every 2–3 years if oligomenorrheic to monitor endometrial thickness and exclude hyperplasia. Hormonal contraception should be continued until conception is actively pursued, with preconception counseling addressing folic acid supplementation, weight optimization, and discontinuation timing. For those undergoing LOD, postoperative pelvic physiotherapy may reduce adhesion-related pain, and serial AMH measurement helps assess ovarian reserve trajectory. Psychological support is integral: validated screening tools (e.g., Hospital Anxiety and Depression Scale) should be administered routinely, given the high prevalence of depression and body image distress in hyperandrogenic women. Finally, patient education—delivered via bilingual (Mandarin–English) digital modules and peer-led support groups—empowers self-management, improves treatment concordance, and fosters resilience across the reproductive lifespan.